Neuro Sector Reviewed by NeuroInvestment
July 07 2008 - 10:50AM
Marketwired
CARDIFF, CA (post-CABG MCI and schizophrenia), Acadia
Pharmaceuticals (Parkinson's psychosis), Avigen (MS spasticity),
Catalyst Pharmaceuticals (cocaine addiction), Ceregene
(Parkinson's), Cortex Pharmaceuticals (AMEX: COR) respiratory
depression), EnVivo Pharmaceuticals (schizophrenia and
Alzheimer's), Evotec (smoking cessation), Medivation
(Huntington's), Neuren (post-CABG MCI), Neurogen (insomnia),
Targacept (NASDAQ: TRGT) with AstraZeneca (schizophrenia and
Alzheimer's), TorreyPines (Sjogren's), Trophos (neuropathic pain).
And many eyes will be tracking the fate of iloperidone/Fanapta's
NDA, important to both Vanda Pharmaceuticals and Titan, as well as
Zogenix's efforts to find a window for its IPO, for which the
climate could hardly be worse.
Recent issues of NeuroInvestment have included our June review
of the Multiple Sclerosis area, featuring information on advanced
programs from BioMS, Biogen-Idec, Active Biotech, and Novartis. The
next issue of NeuroInvestment will be our annual review of the
Alzheimer's area, incorporating what has been learned from the full
and partial failures of recent weeks and assessing the implications
for the rest of the field.
NeuroInvestment is the independent, monthly review of the
neurotherapeutics area. A one-year corporate subscription is $1600,
email or hardcopy. Add $250 for dual delivery, add $50 for airmail
delivery outside North America. A three month trial subscription is
US$600. Individual investor information is available upon
request.
NI Research is the leading publisher of independent research on
the neuropharmaceutical/therapeutic industry. NI Research has
published NeuroInvestment since 1995, the Private CNS Company
Review since 2003, and CNS Disorders/Therapeutics since 2007. NI
Research also provides inlicensing consultation and custom research
for large and small pharmaceutical firms. NI Research has developed
an unmatched information base regarding both publicly and
privately-held neuro-oriented companies.
Contact: NI Research P.O. Box 1028 Cardiff CA 92007 760.230.2581
Email Contact Websites: www.niresearch.com
www.neuroinvestment.com
Cortex Pharm (AMEX:COR)
Historical Stock Chart
From Dec 2024 to Jan 2025
Cortex Pharm (AMEX:COR)
Historical Stock Chart
From Jan 2024 to Jan 2025
Real-Time news about Cortex Pharmaceuticals, (American Stock Exchange): 0 recent articles
More NeuroInvestment News Articles